SCHEMBL2401146

SCHEMBL2401146

C=CCn1cccc1C(=O)c1ccc(C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.52
PPARA Q07869 3/20 0.52
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
ALOX12 P18054 1/20 0.51
RECQL P46063 1/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CXCL8 P10145 1/20 0.40
AKR1B1 P15121 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
GLO1 Q04760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2717815 0.87 ALDH1A1 (0.50) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2718896 0.87 KMT2A (0.47) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL4683444 0.86 ALDH1A1 (0.49) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2723083 0.85 PPARG (0.57) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL30543408 0.83 ALDH1A1 (0.47) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL10151429 0.82 NPC1 (0.56) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2718626 0.82 MAPT (0.77) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2719704 0.80 ALDH1A1 (0.51) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2718628 0.79 ALDH1A1 (0.55) PPARGPPARAALDH1A1LMNAMAPT
SCHEMBL2720808 0.78 PPARG (0.64) PPARGPPARAALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 EP disclosed
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 EP disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 US disclosed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 EP disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
EP-1386913-B1 PYRROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2008-07-16 EP disclosed
EP-1386913-B1 PYRROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2008-07-16 EP disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-20060194857-A1 Novel heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2006-08-31 US disclosed
EP-1647546-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-04-19 EP disclosed
US-20040162331-A1 Pyrrole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-08-19 US disclosed
EP-1386913-A1 PYRROLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES SLC5A1, GLP1R, SLC5A2 PPARG 62/4885PPARA 16/4885ALDH1A1 291/4885
US-20060194857-A1 Novel heteroaryl derivative NR0B1, UGT1A10, NR0B2 PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885
US-20040162331-A1 Pyrrole derivative SLC5A1, GLP1R, SLC5A2 PPARG 126/4885PPARA 31/4885ALDH1A1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.